Crohn’s disease: FORTIFY study (Risankizumab)

This comprehensive study includes several sub-studies to evaluate various aspects of Risankizumab treatment, including maintenance therapy, long-term safety, and patient-reported outcomes. Open-label extensions ensure continuous care for participants.